Lung Cancer Update First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor
Apr 10, 2025
Dr. Justin F Gainor, a medical oncologist from Massachusetts General Hospital, delves into groundbreaking treatments for ALK-positive metastatic non-small cell lung cancer. He discusses the effectiveness of ALK inhibitors, exploring strategies for optimizing treatments and identifying exceptional responders. The conversation highlights the complexities of managing young patients, including family planning and the implications of various therapies. Gainor also addresses the importance of monitoring CNS effects, weight gain challenges, and innovative approaches to treatment resistance.
AI Snips
Chapters
Transcript
Episode notes
Avoid Upfront Whole-Brain Radiation
- Avoid upfront whole-brain radiation in ALK-positive patients due to severe long-term quality of life impact.
- Favor surgery for symptomatic brain lesions needing urgent intervention and start with targeted therapy due to its high intracranial response.
Lorlatinib Neurocognitive Effects
- Neurocognitive side effects of lorlatinib vary widely from subtle changes like irritability to rare severe effects like suicidal ideation.
- Dr. Gainor shares concrete patient examples to educate and set expectations for patients and their families.
Manage Lorlatinib Toxicity by Dose
- Dose reductions for lorlatinib mostly address neurocognitive effects, not cholesterol or weight gain.
- Use other interventions for metabolic issues rather than dose reduction.